Accessibility Menu
Cbd Life Sciences logo

Cbd Life Sciences(OTC) CBDL

Market Cap$1.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-100%
5 Year-100%
1 Year-31%
1 Month+0%
$0.00
+0.00%
+0.00Today
Cbd Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-04
Cbd Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-28
1 month+0%USD 0.002026-08-05
3 month-33.33%USD 0.002026-06-05
Year to date+0%USD 0.002025-12-31
1 year-31.03%USD 0.002025-09-04
3 year-33.33%USD 0.002023-09-05
5 year-99.83%USD 0.122021-09-03
Since inception-100%USD 7,333,333.332012-05-31

Cbd Life Sciences Financials at a Glance

Market Cap

$1.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$80.43K

Net Income (TTM)

-$369.18K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-76.59 (Low)

Price

$0.00

Volume

758,105

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

CBDL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cbd Life Sciences

CBD Life Sciences Inc. specializes in formulating and distributing a broad array of organic items infused with cannabidiol. The company offers a diverse range of natural CBD products, including tinctures, topical oils, and dietary aids, catering to both human and animal consumers.

Products and Services
  • Hemp tinctures for various health benefits
  • Topical massage oils and pain relief balms
  • Specialized products for pets
Growth Outlook
  • Revenue increased to 28,236 in Q4 2025, showing upward momentum
  • Gross profit margin improved to 41.8% in Q4 2025
  • Current ratio of 15.12 indicates strong liquidity position
Financial Highlights
  • Net income of 31,550 reported in Q4 2025
  • Cash and cash equivalents reached 331,598 in Q4 2025
  • Operating cash flow of 32,118 in Q3 2025 demonstrates operational efficiency
CBD Life Sciences Inc. operates in the healthcare sector, focusing on the growing demand for CBD-infused products. The company has shown significant revenue growth, particularly in the last quarter, indicating a positive trend in consumer interest and market penetration. The improvement in gross profit margin reflects better cost management and pricing strategies. With a strong current ratio, CBD Life Sciences Inc. is well-positioned to meet its short-term obligations, which is crucial for sustaining operations and potential expansion. The recent net income and cash flow figures suggest that the company is moving towards profitability, making it an intriguing option for investors interested in the CBD market. Overall, CBD Life Sciences Inc. presents a compelling case for potential investors, with its diverse product offerings and positive financial trends indicating a promising future in the expanding CBD industry.
AI Generated • Aug 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Lisa Nelson

Website

cre8tive.works

Headquarters

Scottsdale, AZ 85259, US

CBDL Financials

Key Financial Metrics (TTM)

Gross Margin

7.80%

Operating Margin

-124.76%

Net Income Margin

-39.99%

Return on Equity

-4.73%

Return on Capital

-13.26%

Return on Assets

-3.42%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.14B

Volume

758.11K

Avg. Volume

5.59M

Financials (TTM)

Gross Profit

$9.96K

Operating Income

-$427.53K

EBITDA

-$405.00K

Operating Cash Flow

-$179.82K

Capital Expenditure

-$0.00

Free Cash Flow

-$179.82K

Cash & ST Invst.

$331.60K

Total Debt

$0.00

Cbd Life Sciences Performance Analysis

Cbd Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 160,241170.4%
20232023-12-31USD 167,1474.3%
20242024-12-31USD 97,302-41.8%
20252025-12-31USD 98,3211.0%
Cbd Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-23.9%
Q12025-03-3138.0%
Q32025-09-30N/A
Q42025-12-3114.7%
Cbd Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.01-95.2%
20232023-12-31USD 0.00N/A
20242024-12-31USD -0.00N/A
20252025-12-31USD 0.00N/A
Cbd Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q12025-03-31100.0%
Q32025-09-30N/A
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$28.24K

+85.4%

Gross Profit

$11.81K

+208.3%

Gross Margin

41.82%

N/A

Market Cap

$1.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$409.57K

N/A

Employees

3

N/A

Net Income

$31.55K

+110.7%

EBITDA

-$26.80K

+90.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$331.60K

+4338.8%

Total Debt

$0.00

N/A

Accounts Receivable

$215.69K

N/A

Inventory

$35.08K

+137.3%

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-3.42%

N/A

Return on Invested Capital

-11.20%

N/A

Free Cash Flow

$0.00

+100.0%

Operating Cash Flow

$0.00

+100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AOXGAoxing Pharmaceutical Company, Inc.
$0.00+0.00%
LRSVLink Reservations Inc.
$0.00+0.00%
GPFTGrapefruit USA, Inc.
$0.00+0.00%
HPMMHemp Naturals, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About CBDL

What is the current price of Cbd Life Sciences?

Cbd Life Sciences is trading at $0.00 per share.

What is the 52-week range for Cbd Life Sciences?

Over the past 52 weeks, Cbd Life Sciences has traded between $0.00 and $0.00.

How much debt does Cbd Life Sciences have?

As of the most recent reporting period, Cbd Life Sciences reported total debt of $0.00.

How much cash does Cbd Life Sciences have on hand?

Cbd Life Sciences reported $331.60K in cash and cash equivalents in its most recent financial results.

What is Cbd Life Sciences’s dividend yield?

Cbd Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services